Abstract
Originalsprog | Engelsk |
---|---|
Tidsskrift | British Journal of Haematology |
Vol/bind | 123 |
Udgave nummer | 2 |
Sider (fra-til) | 253-62 |
Antal sider | 9 |
ISSN | 0007-1048 |
Status | Udgivet - 2003 |
Udgivet eksternt | Ja |
Bibliografisk note
Keywords: Cell Transformation, Neoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Cyclin D1; DNA, Complementary; DNA, Neoplasm; Disease Progression; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oncogene Proteins; Oncogenes; Paraproteinemias; Plasma Cells; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Translocation, GeneticCitationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. / Rasmussen, Thomas; Theilgaard-Mønch, Kim; Hudlebusch, Heidi R; Lodahl, Marianne; Johnsen, Hans E; Dahl, Inger Marie S.
I: British Journal of Haematology, Bind 123, Nr. 2, 2003, s. 253-62.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
AU - Rasmussen, Thomas
AU - Theilgaard-Mønch, Kim
AU - Hudlebusch, Heidi R
AU - Lodahl, Marianne
AU - Johnsen, Hans E
AU - Dahl, Inger Marie S
N1 - Keywords: Cell Transformation, Neoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Cyclin D1; DNA, Complementary; DNA, Neoplasm; Disease Progression; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oncogene Proteins; Oncogenes; Paraproteinemias; Plasma Cells; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic
PY - 2003
Y1 - 2003
N2 - This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.
AB - This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.
M3 - Journal article
C2 - 14531906
VL - 123
SP - 253
EP - 262
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -